For example, patients with mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) and HER2-negative metastatic breast cancer were treated with the monotherapy drug Olaparib (oral PARP inhibitor) [61]. This evidence concerns the gene ERBB2 and breast carcinoma.